ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
